Expert Interview
A Second Opinion: Looking at the recent Phase 3 results on Scholar Rock's apitegromab for Spinal Muscular Atrophy
Ticker(s): SRRK, RHHBF, BHVN, BIIB, NVSInstitution: University of Tennessee Medical Center
- Neuromuscular specialist at UTMC
- Manages several patients with Spinal Muscular Atrophy
- Previous investigator on several neuromuscular clinical trials with a special interest in Chronic Inflammatory Demyelinating Polyneuropathy and Peripheral Neuropathy.
Roughly how many patients with type 2/3 SMA do you treat?
Added By: ben_adminHow do you tend to treat type 2 patients? Type 3?
Added By: ben_adminWhat are your high level thoughts on apitegromab?
Added By: ben_adminCan you talk about your professional background and give details about your clinical practice?
Added By: slingshot_insightsCan you give an overview of the current SMA treatments?
Added By: slingshot_insightsWhat do you think about the mechanism of action of apitegromab, and how might it be helpful for SMA patients?
Added By: slingshot_insightsWhat do you think about the Phase 3 SAPPHIRE trial results for apitegromab, especially regarding dosage and its effect on SMA patients?
Added By: slingshot_insightsHow would you rate your excitement for apitegromab's potential impact, and would you adopt it for your patients if FDA-approved?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
